I
Ivana Ferrero
Researcher at University of Turin
Publications - 58
Citations - 3273
Ivana Ferrero is an academic researcher from University of Turin. The author has contributed to research in topics: Mesenchymal stem cell & Transplantation. The author has an hindex of 23, co-authored 51 publications receiving 2994 citations. Previous affiliations of Ivana Ferrero include Boston Children's Hospital & University of Milan.
Papers
More filters
Journal ArticleDOI
Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial
Letizia Mazzini,Ivana Ferrero,Ivana Ferrero,V. Luparello,Deborah Rustichelli,Monica Gunetti,Katia Mareschi,Katia Mareschi,Lucia Testa,Alessandro Stecco,R. Tarletti,Massimo Miglioretti,E. Fava,N. Nasuelli,Carlo Cisari,Maurilio Massara,R. Vercelli,G.D. Oggioni,Alessandro Carriero,Roberto Cantello,Francesco Monaco,Franca Fagioli +21 more
TL;DR: This study confirms that M SC transplantation into the spinal cord of ALS patients is safe and that MSCs might have a clinical use for future ALS cell based clinical trials.
Journal ArticleDOI
Expansion of Mesenchymal Stem Cells Isolated From Pediatric and Adult Donor Bone Marrow
Katia Mareschi,Ivana Ferrero,Deborah Rustichelli,Simona Aschero,Loretta Gammaitoni,Massimo Aglietta,Enrico Madon,Franca Fagioli +7 more
TL;DR: The enormous plasticity of mesenchymal stem cells (MSCs) suggests an improvement of a standard protocol of isolation and ex vivo expansion for experimental and clinical use and suggests that MSCs can be isolated and expanded from most healthy donors, providing for an autologous source of stem cells.
Journal ArticleDOI
Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis.
Alessandro Vercelli,Alessandro Vercelli,Om Mereuta,Om Mereuta,Diego Garbossa,Diego Garbossa,G Muraca,G Muraca,Katia Mareschi,Deborah Rustichelli,Ivana Ferrero,Letizia Mazzini,Enrico Madon,Franca Fagioli +13 more
TL;DR: Human bone marrow mesenchymal stem cells are a good candidate for ALS cell therapy: they can survive and migrate after transplantation in the lumbar spinal cord, where they prevent astrogliosis and microglial activation and delay ALS-related decrease in the number of motoneurons, thus resulting in amelioration of the motor performance.
Journal ArticleDOI
Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential
L. Valfrè di Bonzo,Ivana Ferrero,Carlo Cravanzola,Katia Mareschi,D Rustichell,Erica Novo,Fiorella Sanavio,Stefania Cannito,E. Zamara,M Bertero,A Davit,S Francica,Francesco Novelli,Sebastiano Colombatto,Franca Fagioli,Maurizio Parola +15 more
TL;DR: Transplanted hMSCs have the potential to migrate into normal and injured liver parenchyma, but differentiation into hepatocyte-like cells is a rare event and pro-fibrogenic potential of hMSC transplant should be not under-evaluated.
Journal ArticleDOI
Stem cell treatment in Amyotrophic Lateral Sclerosis.
Letizia Mazzini,Katia Mareschi,Ivana Ferrero,E. Vassallo,Giuseppe Oliveri,N. Nasuelli,G.D. Oggioni,Lucia Testa,Franca Fagioli +8 more
TL;DR: The results seem to demonstrate that MSCs represent a good chance for stem cell cell-based therapy in ALS and that intraspinal injection of M SCs is safe also in the long term.